254 related articles for article (PubMed ID: 35659256)
21. Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinoma.
Zhao H; Liu H; Kang W; Zhan C; Man Y; Qu T
BMC Med Genomics; 2023 Aug; 16(1):201. PubMed ID: 37626362
[TBL] [Abstract][Full Text] [Related]
22. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
23. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
Zheng F; Liao YJ; Cai MY; Liu YH; Liu TH; Chen SP; Bian XW; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2012 Feb; 61(2):278-89. PubMed ID: 21672940
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration.
Fan K; Zhang CL; Zhang BH; Gao MQ; Sun YC
Sci Rep; 2022 Oct; 12(1):16583. PubMed ID: 36195655
[TBL] [Abstract][Full Text] [Related]
25. DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration.
Xu Y; Jiang Q; Liu H; Xiao X; Yang D; Saw PE; Luo B
J Immunol Res; 2020; 2020():8835393. PubMed ID: 33490290
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of CTCF reduces the binding of EZH2 and affects the methylation of the SOCS3 promoter in hepatocellular carcinoma.
Wei L; Liu Q; Huang Y; Liu Z; Zhao R; Li B; Zhang J; Sun C; Gao B; Ding X; Yu X; He J; Sun A; Qin Y
Int J Biochem Cell Biol; 2020 Mar; 120():105685. PubMed ID: 31917284
[TBL] [Abstract][Full Text] [Related]
27. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
28. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma.
Gu Y; Li X; Bi Y; Zheng Y; Wang J; Li X; Huang Z; Chen L; Huang Y; Huang Y
Aging (Albany NY); 2020 Jan; 12(1):784-807. PubMed ID: 31927532
[TBL] [Abstract][Full Text] [Related]
29. Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.
Wu M; Jiang L
Dig Dis Sci; 2022 Jan; 67(1):146-158. PubMed ID: 33495920
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
32. High mRNA Expression of
Cui Z; Xiao L; Chen F; Wang J; Lin H; Li D; Wu Z
Dis Markers; 2021; 2021():9971799. PubMed ID: 34457090
[TBL] [Abstract][Full Text] [Related]
33. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
Huang B; Huang M; Li Q
Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
[TBL] [Abstract][Full Text] [Related]
34. The role of complement in the clinical course of hepatocellular carcinoma.
Qian X; Yang Z; Gao L; Liu Y; Yan J
Immun Inflamm Dis; 2022 Mar; 10(3):e569. PubMed ID: 34813686
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
36. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.
Tang H; You T; Sun Z; Bai C
BMC Cancer; 2022 Feb; 22(1):197. PubMed ID: 35189839
[TBL] [Abstract][Full Text] [Related]
37. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.
Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699
[TBL] [Abstract][Full Text] [Related]
38. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
[TBL] [Abstract][Full Text] [Related]
39. Six Cell Cycle-related Genes Serve as Potential Prognostic Biomarkers and Correlated with Immune Infiltrates in Hepatocellular Carcinoma.
Shi Y; Sang X; Deng J; Wang Y; Chen X; Lin S; Wu F; Xu A
J Cancer; 2023; 14(1):9-23. PubMed ID: 36605491
[No Abstract] [Full Text] [Related]
40. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
